https://www.optimumcomms.com/wp-content/uploads/2026/01/FundaMental-Pharma_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-06-02 08:32:562026-06-02 08:38:11FundaMental Pharma appoints depression drug developer Dr. Hans Eriksson as Chief Medical Officer to advance its lead treatment-resistant depression candidate
https://www.optimumcomms.com/wp-content/uploads/2026/01/FundaMental-Pharma_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-06-02 08:32:562026-06-02 08:38:11FundaMental Pharma appoints depression drug developer Dr. Hans Eriksson as Chief Medical Officer to advance its lead treatment-resistant depression candidate
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-05-29 10:18:062026-05-29 10:18:06Hansa Biopharma’s CEO Renée Aguiar-Lucander named one of Sweden’s Most Influential Business Women of 2026
https://www.optimumcomms.com/wp-content/uploads/2026/02/Synklino-logo-website.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-05-28 08:41:252026-05-28 08:41:25Synklino announces first patient dosed in Phase 1 trial of SYN002 for CMV prevention in kidney transplantation
https://www.optimumcomms.com/wp-content/uploads/2023/02/ViCentra_Logo_300x180px-3.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-05-28 08:31:132026-05-28 08:31:13ViCentra Scales Commercial Manufacturing, Triples Capacity and Strengthens Unit Economics
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-05-27 09:15:212026-05-27 09:16:12Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation
https://www.optimumcomms.com/wp-content/uploads/2025/09/DaltonTx.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-05-27 08:55:002026-05-27 08:55:00Bonito Biosciences and DaltonTx Announce AI-Driven Collaboration to Advance Precision Delivery for Oligotherapeutics
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-05-26 10:37:032026-05-26 10:37:03Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-05-26 08:52:132026-05-26 08:52:48Poolbeg Pharma plc – pre-IND meeting with the FDA for POLB 001
https://www.optimumcomms.com/wp-content/uploads/2024/05/Template_Logo_300x180px-80x80Web_Logos-1.jpg
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-05-25 16:01:432026-05-25 16:01:43Resolution Therapeutics congratulates University of Edinburgh on positive 4-year MATCH trial data on RMT in liver cirrhosis
https://www.optimumcomms.com/wp-content/uploads/2023/02/StormTx_Logo_300-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-05-22 08:44:022026-05-22 08:44:02STORM Therapeutics to present promising Phase 1 sarcoma data demonstrating activity of first‑in‑class METTL3 inhibitor STC‑15 at ASCO 2026
https://www.optimumcomms.com/wp-content/uploads/2026/03/Mestag_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-05-19 08:33:102026-05-19 08:33:10Mestag Therapeutics Announces the First Patient Dosed with MST-0312 in the Phase I STARLYS Trial
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-05-19 06:35:532026-05-19 06:35:53Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-05-18 16:16:032026-05-18 16:16:23Hansa Biopharma participating at LSX Nordic Congress
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-05-13 10:56:572026-05-18 16:16:56Hansa Biopharma participating at H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-05-13 08:32:402026-05-13 08:32:40Poolbeg Pharma plc – POLB 001 poster to be presented at EHA 2026 Congress
https://www.optimumcomms.com/wp-content/uploads/2024/05/Template_Logo_300x180px-80x80Web_Logos-1.jpg
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-05-12 13:40:502026-05-12 13:40:50Resolution Therapeutics to showcase key preclinical data on its Regenerative Macrophage Therapy (RMT) RTX001 in oral presentation at ASGCT 2026We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
